Breakthrough trial aims to save lives in deadly TB/HIV combination
NCT ID NCT04951986
Summary
This large Phase 3 trial is testing whether adding higher doses of two antibiotics (rifampicin and levofloxacin) for 14 days, with or without steroids, improves survival for adults hospitalized with severe, widespread tuberculosis and HIV. Researchers believe these intensified treatments will kill TB bacteria faster and calm harmful immune responses. The study involves 732 participants and primarily measures whether these approaches reduce deaths within 12 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Khayelitsha Hospital, c/o Steve Biko and Walter Sisulu Drives, Khayelitsha
Cape Town, Western Cape, 7784, South Africa
-
Mitchells Plain Hospital, Mitchells PLain
Cape Town, Western Cape, 7785, South Africa
Conditions
Explore the condition pages connected to this study.